Astellas’ Xtandi bags additional MHRA approval in prostate cancer
Once-daily oral Xtandi approved for the treatment of adult men with metastatic hormone-sensitive prostate cancer
12th May 2021
Latest news
Huma completes $130m funding round to expand digital ‘hospitals at home’ platform
UK healthtech company is now planning to expand platform in the US, Asia and the Middle East
12th May 2021
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
The final guidance publication comes following an appeal against earlier draft recommendations
12th May 2021
New NHS legislation provides ‘once-in-a-decade opportunity’ to centre research
Pharma industry and health leaders react to new legislation and plans outlined in the Queen’s Speech
12th May 2021
MHRA approves label extension for Vertex’s Kaftrio combo
Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain
11th May 2021
Phico Therapeutics raises £7m to advance next-gen antibiotic candidate
Funds will support continued development of company's SASPject platform and progression of lead product PT3.9
11th May 2021
US approves Pfizer COVID-19 vaccine for children aged 12 to 15
First COVID-19 jab to be approved for emergency use in the US for this younger age group
11th May 2021
SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
11th May 2021
Positive CHMP opinion for self-administered Crysvita
Crysvita is used for the treatment of the rare metabolic bone disease X-linked hypophosphataemia (XLH)
10th May 2021
Researchers find CD38-targeting drugs may show promise against prostate cancer
Researchers are initiating clinical trials to evaluate whether targeting the CD38 pathway can provide benefit for people with prostate cancer
10th May 2021
WHO grants Sinopharm’s COVID-19 vaccine emergency approval
First COVID-19 jab developed by a non-Western company to gain this recommendation
10th May 2021
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC
New data presented at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer virtual congress
10th May 2021
Vectura, Inspira team up to develop inhaled COVID-19 drug
The deal will see Vectura test Inspira's inhaled IPX formulation candidates
7th May 2021
Imfinzi, tremelimumab combo boosts survival in lung cancer
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
7th May 2021
Only one week left to enter the Patient Partnership Index 2021
The entry deadline is Friday May 14
7th May 2021
